Osiris Therapeutics Company Profile (NASDAQ:OSIR)

About Osiris Therapeutics (NASDAQ:OSIR)

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:OSIR
  • CUSIP: 68827R10
  • Web: www.osiris.com/
Capitalization:
  • Market Cap: $234.27 million
  • Outstanding Shares: 34,452,000
Average Prices:
  • 50 Day Moving Avg: $6.23
  • 200 Day Moving Avg: $5.42
  • 52 Week Range: $2.67 - $7.39
P/E:
  • Trailing P/E Ratio: 161.90
  • Foreward P/E Ratio: 97.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $86.6 million
  • Price / Sales: 2.71
  • Book Value: $2.32 per share
  • Price / Book: 2.93
Profitability:
  • EBIDTA: $4.41 million
  • Net Margins: -2.60%
  • Return on Equity: -3.13%
  • Return on Assets: -2.59%
Misc:
  • Average Volume: 32,886 shs.
  • Beta: 0.79
  • Short Ratio: 32.7
 

Frequently Asked Questions for Osiris Therapeutics (NASDAQ:OSIR)

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the NASDAQ under the ticker symbol "OSIR."

Who are some of Osiris Therapeutics' key competitors?

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the folowing people:

  • Peter Friedli, Chairman of the Board
  • Jason Keefer, Interim President, Chief Executive Officer, Vice President of Marketing
  • Linda L. Chang, Chief Financial Officer
  • Frank D. Czworka Jr., Vice President, General Manager of Wound Care
  • Adrian P. Mollo, General Counsel
  • Alla N. Danilkovitch Ph.D., Chief Scientific Officer
  • Thomas M. Brandt Jr., Independent Director
  • Thomas J. Knapp, Independent Director
  • Jay M. Moyes, Independent Director
  • Uwe Sommer, Independent Director

Who owns Osiris Therapeutics stock?

Osiris Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Eqis Capital Management Inc. (0.25%). View Institutional Ownership Trends for Osiris Therapeutics.

Who bought Osiris Therapeutics stock? Who is buying Osiris Therapeutics stock?

Osiris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Osiris Therapeutics.

How do I buy Osiris Therapeutics stock?

Shares of Osiris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of Osiris Therapeutics stock can currently be purchased for approximately $6.80.


MarketBeat Community Rating for Osiris Therapeutics (NASDAQ OSIR)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Osiris Therapeutics (NASDAQ:OSIR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Osiris Therapeutics (NASDAQ:OSIR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/16/2016Brean CapitalReiterated RatingSell$4.00N/AView Rating Details
2/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Osiris Therapeutics (NASDAQ:OSIR)
Earnings by Quarter for Osiris Therapeutics (NASDAQ:OSIR)
Earnings History by Quarter for Osiris Therapeutics (NASDAQ OSIR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
5/12/2014($0.08)($0.02)$9.00 million$10.05 millionViewN/AView Earnings Details
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Osiris Therapeutics (NASDAQ:OSIR)
Current Year EPS Consensus Estimate: $0.14 EPS
Next Year EPS Consensus Estimate: $0.07 EPS

Dividends

Dividend History by Quarter for Osiris Therapeutics (NASDAQ OSIR)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2015special$0.209/14/20159/16/20159/30/2015
9/17/2015special$0.2010/14/201510/16/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Osiris Therapeutics (NASDAQ:OSIR)
Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 19.88%
Insider Trades by Quarter for Osiris Therapeutics (NASDAQ:OSIR)
Institutional Ownership by Quarter for Osiris Therapeutics (NASDAQ:OSIR)
Insider Trades by Quarter for Osiris Therapeutics (NASDAQ:OSIR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.21View SEC Filing  
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.28View SEC Filing  
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Osiris Therapeutics (NASDAQ:OSIR)
Latest Headlines for Osiris Therapeutics (NASDAQ:OSIR)
Source:
DateHeadline
rttnews.com logoOsiris Therapeutics Appoints Linda Palczuk As President And CEO
www.rttnews.com - June 27 at 7:12 PM
finance.yahoo.com logoOsiris Therapeutics names new CEO — again
finance.yahoo.com - June 27 at 7:02 AM
feeds.benzinga.com logoOsiris Appoints Linda Palczuk to serve as its President & CEO
feeds.benzinga.com - June 26 at 10:40 AM
prnewswire.com logoCartilage Repair/Regeneration Market is expected to reach USD 6.7 billion by 2025
www.prnewswire.com - June 20 at 12:46 AM
finance.yahoo.com logoOsiris Announces Electronically Available Case Study in a Peer-Reviewed Journal:  Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve
finance.yahoo.com - June 14 at 11:13 PM
marketwatch.com logoCartilage Repair/Regeneration Market Size Worth $6.7 Billion by 2025: Grand View Research, Inc.
www.marketwatch.com - June 6 at 8:29 AM
feeds.benzinga.com logoOsiris Appoints David White to its Board of Directors
feeds.benzinga.com - May 31 at 6:06 PM
bizjournals.com logoCalifornia stem cell agency boss finds new job
www.bizjournals.com - May 2 at 4:52 PM
finance.yahoo.com logoOsiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and …
finance.yahoo.com - April 14 at 5:11 AM
finance.yahoo.com logoOsiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
finance.yahoo.com - April 13 at 6:52 PM
finance.yahoo.com logoOsiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
finance.yahoo.com - April 7 at 11:46 AM
finance.yahoo.com logoOsiris Therapeutics Announces Change in its Board of Directors
finance.yahoo.com - March 31 at 7:10 PM
finance.yahoo.com logoOSIRIS THERAPEUTICS, INC. Financials
finance.yahoo.com - March 30 at 7:22 PM
finance.yahoo.com logoOsiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
finance.yahoo.com - March 30 at 7:22 PM
globenewswire.com logoOsiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements - GlobeNewswire (press release)
globenewswire.com - March 28 at 6:51 PM
finance.yahoo.com logoOsiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements
finance.yahoo.com - March 27 at 6:34 PM
rttnews.com logoOsiris Therapeutics Inc. (OSIR) Tumbled After NASDAQ Moves To Delist
www.rttnews.com - March 14 at 10:27 AM
finance.yahoo.com logoNASDAQ Decides to Delist Osiris Therapeutics, Pulmatrix Deals with Research Cost Overruns
finance.yahoo.com - March 14 at 10:27 AM
bizjournals.com logoOsiris shares tumble on delisting notice from Nasdaq
www.bizjournals.com - March 13 at 6:46 PM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S
us.rd.yahoo.com - March 10 at 8:51 PM
us.rd.yahoo.com logo5:33 pm Osiris Therapeutics will be suspended at the opening of business on March 14, 2017; anticipates that its common stock will be quoted on the Pink OTC Markets
us.rd.yahoo.com - March 10 at 8:51 PM
finance.yahoo.com logoStem Cell Therapy Market Worth 145.8 Million USD by 2021
finance.yahoo.com - February 28 at 10:46 AM
prnewswire.com logoRegenerative Medicine Market Growing at a CAGR of 23.6 % During 2016 to 2021
www.prnewswire.com - February 16 at 6:40 PM
prnewswire.com logoRegenerative Medicine Market Worth 38.70 Billion USD by 2021
www.prnewswire.com - February 10 at 8:02 PM
finance.yahoo.com logoOsiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
finance.yahoo.com - February 10 at 8:02 PM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
biz.yahoo.com - February 10 at 8:02 PM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 8 at 8:03 PM
nasdaq.com logoMid-Afternoon Market Update: Celestica Rises On Earnings Beat; KEYW Shares Slide - Nasdaq
www.nasdaq.com - January 30 at 12:34 AM
globenewswire.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in ... - GlobeNewswire (press release)
globenewswire.com - January 20 at 4:45 AM
globenewswire.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on the ...
globenewswire.com - January 19 at 11:44 PM
finance.yahoo.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in Wound Management is Available Electronically in a Peer-Reviewed Journal
finance.yahoo.com - January 19 at 11:44 PM
finance.yahoo.com logoOsiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties of Cryopreserved Viable Amnion is Available Electronically in Peer-Reviewed Journal
finance.yahoo.com - January 13 at 11:58 PM
finance.yahoo.com logo5:04 pm Osiris Therapeutics announced that new peer-reviewed manuscript 'Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds' was published in Journal of Diabetic Foot Complications
finance.yahoo.com - January 13 at 11:58 PM

Social

Chart

Osiris Therapeutics (OSIR) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff